Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

SurModics bolsters drug delivery IP; reports strong FY08

This article was originally published in Clinica

  • News

Executive Summary

SurModics has strengthened its drug delivery business after purchasing certain IP assets from PR Pharmaceuticals (PRP), a Fort Collins, Colorado-based specialist in injectable, biodegradable, sustained-release formulations. SurModics will gain PRP's protein delivery capabilities and its know-how in delivering injectable microparticles through smaller-gauge needles. The latter is used in ophthalmic applications – an area in which SurModics is particularly – as well as in subcutaneous or intramuscular injections. In addition to the IP, Eden Prairie, Minnesota-based SurModics will also take over several customer-paid development projects from PRP, as well as be a paid development partner for PRP's proprietary basal insulin product InsuLAR.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT043372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By